絞り込み

17307

広告

Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

著者 Konstantinidis L , Mameletzi E , Mantel I , Pournaras JA , Zografos L , Ambresin A
Graefes Arch Clin Exp Ophthalmol.2009 Sep ; 247(9):1165-71.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Hôpital Ophtalmique Jules Gonin, University of Lausanne, 1004 Lausanne, Switzerland.

スターを付ける スターを付ける     (304view , 0users)

Full Text Sources

Medical

Miscellaneous

Retinal angiomatous proliferation (RAP) is a distinct variant of neovascular age-related macular degeneration (AMD). The aim of this study is to evaluate the functional and anatomic outcome after intravitreal ranibizumab (Lucentis) treatment in patients with RAP.
PMID: 19404661 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード